Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines

References

• Dowsett M, Cooke T, Ellis I, Gullick WJ, Gusterson B, Mallon E, Walker R. Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer. 2000;36(2):170–176.
   PubMed Web of Science ®Google Scholar
• Kim H, Muller WJ. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp Cell Res. 1999;253(1):78–87.
   PubMed Web of Science ®Google Scholar
• Koeppen HKW, Wright BD, Burt AD, Quirke P, McNicol AM, Dybdal NO, Sliwkowski MX, Hillan KJ. Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology. 2001;38(2):96–104.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–137.
   PubMed Web of Science ®Google Scholar
• Tiwari SR, Mishra P, Abraham J. A novel HER2-targeted tyrosine kinase inhibitor. Clin Breast Cancer. 2016;16(5):344–348.
   PubMed Web of Science ®Google Scholar
• Johnston SR, Leary A. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today. 2006;42(7):441–453.
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramon y Cajal S, Arribas J, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2009;28(6):803–814.
   PubMed Web of Science ®Google Scholar
• Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004;64(18):6652–6659.
   PubMed Web of Science ®Google Scholar
• Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Gale C-M, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, et al. PF00299804, an irreversible Pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007;67(24):11924–11932.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786–792.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong K-K, Tenen DG, Halmos B. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005;65(16):7096–7101.
   PubMed Web of Science ®Google Scholar
• Yun C-H, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong K-K, Meyerson M, Eck MJ. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008;105(6):2070–2075.
   PubMed Web of Science ®Google Scholar
• Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin A-M, Gilmer TM. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 2009;69(17):6871–6878.
   PubMed Web of Science ®Google Scholar
• Wang Q, Quan H, Zhao J, Xie C, Wang L, Lou L. RON confers lapatinib resistance in HER2-positive breast cancer cells. Cancer Lett. 2013;340(1):43–50.
   PubMed Web of Science ®Google Scholar
• Rexer BN, Ham AJL, Rinehart C, Hill S, de Matos Granja-Ingram N, Gonzalez-Angulo AM, Mills GB, Dave B, Chang JC, Liebler DC, et al. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene. 2011;30(40):4163–4174.
   PubMed Web of Science ®Google Scholar
• Eichhorn PJA, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 2008;68(22):9221–9230.
   PubMed Web of Science ®Google Scholar
• Lancini GC, Arioli V, Lazzari E, Bellani P. Synthesis and relationship between structure and activity of 2-nitroimidazole derivatives. J Med Chem. 1969;12(5):775–780.
   PubMed Web of Science ®Google Scholar
• Noss MB, Panicucci R, McClelland RA, Rauth AM. 1-Methyl-2-nitrosoimidazole: cytotoxic and glutathione depleting capabilities. Int J Radiat Oncol Biol Phys. 1989;16(4):1015–1019.
   PubMed Web of Science ®Google Scholar
• Hoigebazar L, Jeong JM, Lee JY, Shetty D, Yang BY, Lee YS, Lee DS, Chung JK, Lee MC. Syntheses of 2-nitroimidazole derivatives conjugated with 1,4,7-triazacyclononane-N,N′-diacetic acid labeled with F-18 using an aluminum complex method for hypoxia imaging. J Med Chem. 2012;55(7):3155–3162.
   PubMed Web of Science ®Google Scholar
• Kumar P, Shustov G, Liang H, Khlebnikov V, Zheng W, Yang XH, Cheeseman C, Wiebe LI. Design, synthesis, and preliminary biological evaluation of 6-O-glucose-azomycin adducts for diagnosis and therapy of hypoxic tumors. J Med Chem. 2012;55(13):6033–6046.
   PubMed Web of Science ®Google Scholar
• van Loon J, Janssen MH, Ollers M, Aerts HJ, Dubois L, Hochstenbag M, Dingemans AM, Lalisang R, Brans B, Windhorst B, et al. PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging. 2010;37(9):1663–1668.
   PubMed Web of Science ®Google Scholar
• Cheng W, Zhu S, Ma X, Qiu N, Peng P, Sheng R, Hu Y. Design, synthesis and biological evaluation of 6-(nitroimidazole-1H-alkyloxyl)-4-anilinoquinazolines as efficient EGFR inhibitors exerting cytotoxic effects both under normoxia and hypoxia. Eur J Med Chem. 2015;89:826–834.
   PubMed Web of Science ®Google Scholar
• Elkamhawy A, Son S, Lee HY, El-Maghrabey MH, Hamd MAE, Alshammari SO, Abdelhameed AA, Alshammari QA, Abdeen A, Ibrahim SF, et al. Design, synthesis, biological evaluation, and molecular dynamics studies of novel lapatinib derivatives. Pharmaceuticals. 2022;16(1):43.
   Web of Science ®Google Scholar
• Ishikawa T, Seto M, Banno H, Kawakita Y, Oorui M, Taniguchi T, Ohta Y, Tamura T, Nakayama A, Miki H, et al. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. J Med Chem. 2011;54(23):8030–8050.
   PubMed Web of Science ®Google Scholar
• Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS, Wallen EM, Crane JM, Moore DT, Grigson G, et al. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urol Oncol. 2013;31(1):82–86.
   PubMed Web of Science ®Google Scholar
• Jathal MK, Steele TM, Siddiqui S, Mooso BA, D'Abronzo LS, Drake CM, Whang YE, Ghosh PM. Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase. Br J Cancer. 2019;121(3):237–248.
   PubMed Web of Science ®Google Scholar
• Rashed FB, Diaz-Dussan D, Mashayekhi F, Macdonald D, Nation PN, Yang XH, Sokhi S, Stoica AC, El-Saidi H, Ricardo C, et al. Cellular mechanism of action of 2-nitroimidazoles as hypoxia-selective therapeutic agents. Redox Biol. 2022;52:102300.
   PubMed Web of Science ®Google Scholar
• Soliman AM, Alqahtani AS, Ghorab MM. Novel sulfonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers. J Enzyme Inhib Med Chem. 2019;34(1):1030–1040.
   PubMed Web of Science ®Google Scholar
• Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem. 2002;277(48):46265–46272.
   PubMed Web of Science ®Google Scholar
• Chemical Computing Group Inc. Molecular operating environment (MOE). Montreal: Chemical Computing Group Inc.; 2016. p. 1010.
   Google Scholar
• Madbouly E, Lashine E-S, Al-Karmalawy AA, Sebaiy M, Pratsinis H, Kletsas D, Metwally K. Design and synthesis of novel quinazolinone-chalcone hybrids as potential apoptotic candidates targeting caspase-3 and PARP-1: in vitro, molecular docking, and SAR studies. New J Chem. 2022;46(46):22013–22029.
   Web of Science ®Google Scholar
• Elkamhawy A, Farag AK, Viswanath AN, Bedair TM, Leem DG, Lee KT, Pae AN, Roh EJ. Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: design, synthesis, kinase assay, cell-based assay, and molecular docking. Bioorg Med Chem Lett. 2015;25(22):5147–5154.
   PubMed Web of Science ®Google Scholar
• Lee K, Nada H, Byun HJ, Lee CH, Elkamhawy A. Hit identification of a novel quinazoline sulfonamide as a promising EphB3 inhibitor: design, virtual combinatorial library, synthesis, biological evaluation, and docking simulation studies. Pharmaceuticals. 2021;14(12):1247.
   Web of Science ®Google Scholar
• Elsherbeny MH, Ammar UM, Abdellattif MH, Abourehab MAS, Abdeen A, Ibrahim SF, Abdelrahaman D, Mady W, Roh EJ, Elkamhawy A. 2-(3-Bromophenyl)-8-fluoroquinazoline-4-carboxylic acid as a novel and selective aurora a kinase inhibitory lead with apoptosis properties: design, synthesis, in vitro and in silico biological evaluation. Life. 2022;12(6):876.
   PubMedGoogle Scholar
• Salem MA, El-Shiekh RA, Aborehab NM, Al-Karmalawy AA, Ezzat SM, Alseekh S, Fernie AR. Metabolomics driven analysis of Nigella sativa seeds identifies the impact of roasting on the chemical composition and immunomodulatory activity. Food Chem. 2023;398:133906.
   PubMed Web of Science ®Google Scholar
• Kutkat O, Moatasim Y, Al-Karmalawy AA, Abulkhair HS, Gomaa MR, El-Taweel AN, Abo Shama NM, GabAllah M, Mahmoud DB, Kayali G, et al. Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies. Sci Rep. 2022;12(1):12920.
   PubMed Web of Science ®Google Scholar
• Mahmoud A, Mostafa A, Al-Karmalawy AA, Zidan A, Abulkhair HS, Mahmoud SH, Shehata M, Elhefnawi MM, Ali MA. Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies. Heliyon. 2021;7(9):e07962.
   PubMed Web of Science ®Google Scholar
• Hammoud MM, Khattab M, Abdel-Motaal M, Van der Eycken J, Alnajjar R, Abulkhair H, Al‐Karmalawy AA. Synthesis, structural characterization, DFT calculations, molecular docking, and molecular dynamics simulations of a novel ferrocene derivative to unravel its potential antitumor activity. J Biomol Struct Dyn. 2022;1–18.
   Google Scholar
• Ezz Eldin RR, Saleh MA, Alotaibi MH, Alsuair RK, Alzahrani YA, Alshehri FA, Mohamed AF, Hafez SM, Althoqapy AA, Khirala SK, et al. Ligand-based design and synthesis of N′-Benzylidene-3,4-dimethoxybenzohydrazide derivatives as potential antimicrobial agents; evaluation by in vitro, in vivo, and in silico approaches with SAR studies. J Enzyme Inhib Med Chem. 2022;37(1):1098–1119.
   PubMed Web of Science ®Google Scholar
• El-Masry RM, Al-Karmalawy AA, Alnajjar R, Mahmoud SH, Mostafa A, Kadry HH, Abou-Seri SM, Taher AT. Newly synthesized series of oxoindole–oxadiazole conjugates as potential anti-SARS-CoV-2 agents: in silico and in vitro studies. New J Chem. 2022;46(11):5078–5090.
   Web of Science ®Google Scholar
• Mansour KA, Elbermawi A, Al-Karmalawy AA, Lahloub M-F, El-Neketi M. Cytotoxic effects of extracts obtained from plants of the Oleaceae family: bio-guided isolation and molecular docking of new secoiridoids from Jasminum humile. Pharm Biol. 2022;60(1):1374–1383.
   PubMed Web of Science ®Google Scholar